A Breakthrough Approach to Treatment-Resistant Depression
For patients with treatment-resistant depression (TRD), finding an effective therapy can feel like chasing a moving target. Traditional antidepressants often fall short, especially for those who have tried multiple medications without success. Now, a novel NR2B negative allosteric modulator called onfasprodil (MIJ821) is showing exciting potential for fast and sustained relief.
What Is Onfasprodil and How Does It Work?
Onfasprodil is a selective modulator that targets the NR2B subunit of the NMDA receptor, a key player in brain signaling. Unlike typical antidepressants that take weeks to work, onfasprodil works quickly—similar to ketamine—but with a different mechanism and potentially fewer side effects.
This new compound falls under a class of innovative glutamatergic therapies that affect how the brain processes emotions, pain, and cognition. Researchers believe that targeting the NR2B receptor could offer a safer alternative to ketamine with lasting benefits.
Clinical Trial Shows Rapid Relief Within 24 Hours
In a recent phase 2, randomized, placebo-controlled study, researchers tested different doses of onfasprodil in adults with TRD. Patients had already failed to respond to at least two other antidepressants. They received either a low or high dose of onfasprodil once or twice per week, ketamine as a comparison, or a placebo over a 6-week period.
The results were striking:
- Within 24 hours, patients receiving onfasprodil had significantly greater reductions in depression symptoms compared to placebo.
- At 48 hours, these effects remained strong, with onfasprodil performing similarly—or even better—than ketamine in some cases.
- At 6 weeks, the lower dose of onfasprodil continued to show meaningful improvement in depression scores.
Onfasprodil’s Safety Profile
Unlike some rapid-acting treatments that come with a high risk of dissociation or sedation, onfasprodil was well tolerated overall. The most common side effects were mild, including dizziness, temporary memory lapses, and drowsiness. No serious safety concerns were flagged, making it a promising candidate for ongoing research.
Comparing to Ketamine
While ketamine infusion therapy has gained attention for its fast-acting benefits in depression, it comes with challenges such as potential misuse, dissociation, and the need for close monitoring. Onfasprodil appears to offer a similarly fast onset without some of these complications, especially at lower doses.
This makes it a strong candidate for those seeking a new option for TRD without the intense effects often associated with ketamine or esketamine (Spravato).
The Future of Antidepressant Innovation
This study supports the growing shift in psychiatry toward novel, rapid-acting treatments that go beyond serotonin and other traditional neurotransmitters. Therapies like onfasprodil are pushing the boundaries of what’s possible—offering hope to those left behind by conventional care.
With further trials, we may see NR2B modulators become a new tool in treating not just TRD, but potentially other mood disorders, especially when integrated into multimodal approaches such as neurofeedback or light therapy.
Citations:
- Shelton, R. C., et al. (2025). Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821). The Journal of Clinical Psychiatry. https://doi.org/10.4088/JCP.23m15246
- ClinicalTrials.gov. (n.d.). Study of MIJ821 in Participants With Treatment-Resistant Depression (NCT03756129). https://clinicaltrials.gov/study/NCT03756129
Subscribe to IPN to stay update with Interventional Psychiatry.